The BioSecure Act as an example of displacing China in strategically important sectors

The United States, using the case of a specific industry, demonstrates its approach to eliminating China’s influence in strategically important sectors by responding to its “toxic behavior.”

A landmark example of this was the deal announced on December 24, 2024, when the Chinese company WuXi AppTec announced that its subsidiaries had signed an agreement with the American private equity firm Altaris LLC to sell its cell and gene therapy manufacturing unit.

The key reason for this sale was the passage of the BioSecure Act by the House of Representatives in September 2024, which blocks access to government funding for medical companies that have partnerships with autocratic countries such as China, Russia, Iran, North Korea, and Cuba.